Dactinomycin

General description

Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).

INN	Dactinomycin
ATC codes	L01DA01
Medicine type	Chemical agent
EML status history	First added in 1984 (TRS 722) for Malignant trophoblastic neoplasms of placenta Changed in 1984 (TRS 722) for Rhabdomyosarcoma primary site Changed in 1984 (TRS 722) for Malignant neoplasms of kidney, except renal pelvis Changed in 1984 (TRS 722) for Unspecified malignant neoplasms of unspecified sites Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of unspecified sites Added in 2021 (TRS 1035) for Ewing sarcoma of bone or articular cartilage of unspecified sites
Wikipedia	Dactinomycin
DrugBank	Dactinomycin

Recommendations

Section Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Rhabdomyosarcoma primary site

Malignant neoplasms of kidney, except renal pelvis

Unspecified malignant neoplasms of unspecified sites

Ewing sarcoma of bone or articular cartilage of unspecified sites